From the Department of Neurological Sciences, University of Palermo, Palermo, Italy (Drs. Brighina, Salemi, Fierro, Gasparro); Neurology Unit, Hospital Villa Sofia, Palermo, Italy (Drs. Brighina, Salemi, Fierro, Gasparro); Department of Neuroscience, Civic Hospital, Palermo, Italy (Drs. Balletta and Aloisio); Unit of Neurodegenerative Diseases, Caltanissetta, Italy (Dr. La Pegna); Neurology Unit, Hospital S. Elia, Caltanissetta, Italy (Dr. Randisi); Neurology Outpatient Service, Palermo, Italy (Dr. Saporito); Civic Hospital, Partinico, Palermo, Italy (Dr. Calagna); Department of Neurology, University of Catania, Catania, Italy (Drs. La Naia and Morana).
A Validation Study of an Italian Version of the “ID Migraine”
Article first published online: 18 JUL 2008
Headache: The Journal of Head and Face Pain
Volume 47, Issue 6, pages 905–908, June 2007
How to Cite
Brighina, F., Salemi, G., Fierro, B., Gasparro, A., Balletta, A., Aloisio, A., La Pegna, G., Randisi, G., Saporito, V., Calagna, G., La Naia, F. and Morana, R. (2007), A Validation Study of an Italian Version of the “ID Migraine”. Headache: The Journal of Head and Face Pain, 47: 905–908. doi: 10.1111/j.1526-4610.2006.00628.x
- Issue published online: 13 NOV 2008
- Article first published online: 18 JUL 2008
- Accepted for publication June 15, 2006.
- migraine burden;
- migraine screening instruments;
- ID Migraine
Background.—Migraine is a highly prevalent and disabling disease which is substantially underdiagnosed in primary care. Recently, the ID Migraine, a self-administered questionnaire, consisting of only 3 items, was shown to be a valid and reliable screening instrument for migraine in primary care in the United States.
Objective.—The aim of the present study was to validate an Italian version of the “ID Migraine” questionnaire.
Methods.—Two hundred and twenty-two consecutive headache patients referring to 8 headache centers in Sicily (Italy) completed an Italian version of the ID Migraine. The responses to the questionnaire were compared with the diagnosis of headache made by a headache specialist blind to the result of the questionnaire. Sensitivity, specificity, positive and negative predictive values for migraine were calculated.
Results.—The statistical analysis of 222 patients examined showed a very good performance of the ID Migraine with high sensitivity: 0.95 (95% CI, 0.91 to 0.98), specificity: 0.72 (95% CI, 0.62 to 0.82), and positive predictive value: 0.88 (95% CI, 0.82 to 0.93). ID Migraine showed also a very good accuracy level: 0.87 (95% CI, 0.83 to 0.92).
Conclusion.—This validation study showed “ID Migraine” as a valid tool for migraine screening also in Italian patients referring to headache centers. If confirmed in a primary care setting, these results establish the “ID Migraine” as a valid screening instrument for migraine in Italian population.